Effects of Empagliflozin in Reducing Oxidative Stress After Kidney Transplantation
NCT ID: NCT04918407
Last Updated: 2025-09-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2022-01-01
2025-08-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Empagliflozin in NODAT
NCT03642184
Randomized Trial of SGLT2i in Heart Transplant Recipients
NCT06625073
Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients
NCT04965935
Empagliflozin in Heart Failure Dialysis Patients
NCT05967156
Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease
NCT05465317
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Empagliflozin
Adding 25mg Empagliflozin on Insulin
Empagliflozin 25 MG
25 mg
Insulin
Insulin
Insulin alone
Just contriling the blood glucose with Insulin
Insulin
Insulin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Empagliflozin 25 MG
25 mg
Insulin
Insulin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HbA1c: 6.5-9.0%
* post kidney transplant
* stable graft function
Exclusion Criteria
* history of recurrent urinary tract infection
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shahid Beheshti University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
nooshin dalili
Assistant Professor of SBMU
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nooshin Dalili
Role: PRINCIPAL_INVESTIGATOR
Shahid Beheshti University of Medical Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Labbafinezhd Hospital
Tehran, , Iran
SBMU
Tehran, , Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SBMU98543
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.